Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy.
AffiliationThe Christie NHS Foundation Trust, Manchester, UK. Electronic address: firstname.lastname@example.org.
MetadataShow full item record
AbstractRoutine use of I-125 interstitial brachytherapy (BT) alone in intermediate risk (IR) prostate cancer is controversial. It is often combined with external beam radiotherapy (EBRT). The biochemical outcome of a large cohort of only IR disease treated with BT monotherapy is reported.
CitationBiochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy. 2013: Radiother Oncol
JournalRadiotherapy and Oncology